Protocol #28821: A Phase III, randomized, double-blind,

Project: Research project

Project Details

Description

Protocol #28821: A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS
StatusFinished
Effective start/end date12/1/0811/30/12

Funding

  • EMD Serono, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.